teva pharmaceutical ind ltd
Transactions by TEVA PHARMACEUTICAL IND LTD (TEVA) in the last 6 months
Teva Pharmaceutical Industries Limited (NYSE:TEVA) entered into an agreement to acquire 51% stake in Immuneering Corporation on August 3, 2015.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) signed a definitive agreement to acquire Allergan Generics from Allergan plc (NYSE:AGN) for $40.5 billion in cash and stock on July 26, 2015. On closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion, representing a 10% ownership stake in Teva. Allergan Generics is being acquired as cash free and debt free basis. Teva will pay Allergan $33.75 billion in cash which will ...
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) acquired 22 generic drug products from Teva Pharmaceutical Industries Limited (NYSE:TEVA) for $25 million on July 10, 2015. ANI Pharmaceuticals will pay $25 million in cash and a percentage of future gross profits from product sales. The acquisition is being funded through cash on hand.
Microchips Biotech, Inc. announced that it will receive $18,648,546 in funding on June 17, 2015. The company will issue common stock in the transaction. The transaction will include participation from five investors. The company will issue securities pursuant to exemption provided under Regulation D.
On June 18, 2015, the company amended the terms of the transaction. The company announced that it has entered in to an agreement to receive $35,000,000 in an equity funding ...
American Well Corporation announced that it will receive tens of millions of dollars funding from new investor, Teva Pharmaceutical Industries Limited on June 2, 2015.
Soros Fund Management LLC sold all of its 0.6% stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the first quarter of 2015. Soros Fund Management sold all the 4.9 million shares of Teva held by it.
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) acquired New Drug Application for Testosterone Gel from Teva Pharmaceutical Industries Limited (NYSE:TEVA) for $5 million on May 13, 2015. Upon commercialization, ANI will pay Teva up to $5 million at a rate of 5% of the consideration received by ANI as a result of commercial sale of the product.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) made a proposal to acquire Mylan N.V. (NasdaqGS:MYL) for $31 billion on April 21, 2015. Teva offered $82 a share in cash and stock for Mylan. The consideration would comprise of approximately 50% cash and 50% stock. The proposal was unanimously approved by the Board of Directors of Teva. This proposal is subject to customary conditions. The transaction would not be subject to a financing condition or require a Teva stockholder ...
Paulson & Co. Inc.
The Goldman Sachs Group, Inc.
Spinath & Wakkie
Teva Pharmaceutical Industries Limited (NYSE:TEVA) entered into a definitive agreement to acquire Auspex Pharmaceuticals, Inc. (NasdaqGM:ASPX) from a group of shareholders for $3.2 billion in cash on March 29, 2015. The group of shareholders includes Thomas, McNerney & Partners, Panorama Capital, CMEA Capital, Foresite Capital Management, L.L.C. and other shareholders. Under the terms of the deal, Teva will commence a tender offer for all of the outstanding shares of ...
Deerfield Capital, L.P.
Deerfield Management Company, L.P.
Deerfield Private Design Fund II, L.P.
Deerfield Private Design International II, Ltd.
Deerfield Special Situations Fund, LP
Deerfield Special Situations International Master Fund, L.P.
Foresite Capital Mangement, LLC
Oxford Finance LLC
Panorama Capital I, L.P.
Presidio Partners 2007
Thomas, McNerney & Partners
Thomas, McNerney & Partners II, L.P.
|Abbott Laboratories||$44.14 USD||-0.10|
|AbbVie Inc||$61.58 USD||+0.60|
|AstraZeneca PLC||4,248 GBp||+130.50|
|Eli Lilly & Co||$81.60 USD||-0.21|
|Medtronic PLC||$69.98 USD||-1.57|
|View Industry Companies|